


Figure 1. Flow of participants



Legend:

PA – primary aldosteronism

PAC – plasma aldosterone concentration

PRA – plasma renin activity

Index test criteria – PAC > 20 ng/dL plus PRA < 0.6 ng/ml/hr with spontaneous hypokalemia

Table 1. Clinical characteristics between primary aldosteronism (PA) and non-PA patients (n=120)

	All (n=120)	PA (n=79)	Non-PA (n=41)	p-value
	Mean $\pm$ SD; Median (IQR); Frequency (%)			
Age, years	49.94 $\pm$ 11.00	48.92 $\pm$ 11.75	51.90 $\pm$ 9.21	0.131*
Sex at birth				0.888**
Male	42 (35.0)	28 (35.4)	14 (34.1)	
Female	78 (65.0)	51 (64.6)	27 (65.9)	
Hypertension	101 (91.8)	70 (93.3)	31 (88.6)	.462†
Diabetes mellitus	32 (29.9)	24 (33.3)	8 (22.9)	.267**
Chronic kidney disease				.681**
Stage (based from 2021				
CKD-EPI eGFR ml/min/1.73				
m ²) (n=102)				
G1 ($\geq$ 90)	59 (57.8)	37 (54.4)	22 (64.7)	
G2 (60-89)	31 (30.4)	23 (33.8)	8 (23.5)	
G3a (45-59)	10 (9.8)	7 (10.3)	3 (8.8)	
G3b (30-44)	2 (2.0)	1 (1.5)	1 (2.9)	
Spontaneous hypokalemia	71 (61.2)	51 (65.4)	20 (52.6)	.186**
Baseline plasma	18.49 (11.73-	20.46 (13.73-	13.25 (8.51-	0.004‡
aldosterone concentration	27.67)	32.93)	23.21)	
(PAC), ng/dL				
Baseline plasma renin activity	0.28 (0.15-	0.27 (0.15-	0.29 (0.14-	0.861‡
(PRA), ng/ml/h	0.52)	0.51)	0.54)	
Baseline Aldosterone-renin	62.29 (32.09-	76.36 (36.21-	40.59 (31.08-	0.059‡
ratio (ARR), ng/dL/ng/ml/h	140.75)	145.29)	107.22)	

Statistical tests used: *, Independent t-test; **, Pearson Chi-Square test; †, Fisher's Exact test; ‡, Mann-Whitney U test

Table 2. CT-scan findings and histopathology in patients with positive saline infusion test (n=79)

	Frequency (%)
Abdominal CT done	65 (82.3)
Laterality	
Bilateral nodule	5 (7.69)
Unilateral nodule	48 (73.85)
No discrete nodule seen	12 (18.46)
Surgery done	19 (24.1)
Histopathology	
Adrenocortical adenoma	14 (73.68)
Adrenocortical carcinoma	1 (5.26)
Adrenocortical neoplasm	2 (10.53)
Endothelial cyst	1 (5.26)
Missing histopathology	1 (5.26)

Table 3. Diagnostic performance of laboratory findings for primary aldosteronism

	Sensitivity, %	Specificity, %	PPV, %	NPV, %	LR+	LR-	Accuracy, %
	Estimate (95% CI)						
3 combinations							
A1: PAC > 10 ng/dL + PRA < 1.0 ng/dL/hr + spont. hypoK	48.00% (36.31 – 59.85%)	69.70% (51.29 – 84.41%)	78.26% (67.09 – 86.41%)	37.10% (30.13 – 44.64%)	1.58 (0.90 - 2.80)	0.75 (0.55 - 1.02)	54.63% (44.76 - 64.24%)
A2: PAC > 15 ng/dL + PRA < 1.0 ng/dL/hr + spont. hypoK	44.00% (32.55 - 55.94%)	81.82% (64.54 – 93.02%)	84.62% (71.85 – 92.22%)	39.13% (33.20 – 45.40%)	2.42 (1.12 – 5.21)	0.68 (0.53 - 0.89)	55.56% (45.68 - 65.12%)
A3: PAC > 20 ng/dL + PRA < 1.0 ng/dL/hr + spont. hypoK	34.67% (24.04 - 46.54%)	87.88% (71.80 - 96.60%)	86.67% (71.14 – 94.49%)	37.18% (32.47 – 42.15%)	2.86 (1.08 - 7.54)	0.74 (0.60 - 0.92)	50.93% (41.13 - 60.67%)
A4: PAC > 25 ng/dL + PRA < 1.0 ng/dL/hr + spont. hypoK	26.67% (17.11 - 38.14%)	100.00% (89.42 - 100.00%)	100.00%	37.65% (34.36 – 40.75%)	-	0.73 (0.64 - 0.84)	49.07% (39.33 – 58.87%)
A5: PAC > 10 ng/dL + PRA < 0.6 ng/dL/hr + spont. hypoK	45.33% (33.79 – 57.25%)	72.73% (54.48 - 86.70%)	79.07% (67.24 – 87.43%)	36.92% (30.39 – 43.98%)	1.66 (0.90 – 3.06)	0.75 (0.56 - 1.01)	53.70% (43.85 – 63.35%)
A6: PAC > 15 ng/dL + PRA < 0.6 ng/dL/hr + spont. hypoK	41.33% (30.08 - 53.30%)	87.88% (71.80 – 96.60%)	88.57% (74.84 - 95.28%)	39.73% (34.41 - 45.30%)	3.41 (1.31 – 8.88)	0.67 (0.53 - 0.84)	55.56% (45.68 – 65.12%)
A7: PAC > 20 ng/dL + PRA < 0.6 ng/dL/hr + spont. hypoK	34.67% (24.04 - 46.54%)	93.94% (79.77 - 99.26%)	92.86% (76.61 – 98.10%)	38.75% (34.43 – 43.25%)	5.72 (1.44 - 22.71)	0.70 (0.58 - 0.84)	52.78% (42.94 - 62.46%)
A8: PAC > 25 ng/dL + PRA < 0.6 ng/dL/hr + spont. hypoK	26.67% (17.11 - 38.14%)	100.00% (89.42 - 100.00%)	100.00%	37.50% (34.36 – 40.75%)	-	0.73 (0.64 - 0.84)	49.07% (39.33 – 58.87%)
2 Combinations							
B1: PAC > 10 ng/dL + PRA <	78.67% (67.68 - 87.29%)	34.29% (19.13 – 52.21%)	71.95% (66.27 – 77.01%)	42.86% (28.51 – 58.52%)	1.20 (0.92 - 1.56)	0.62 (0.33 - -	64.55% (54.85 - 73.43%)

[illegible]